APS-1 patients carry AIRE mutations that lead to autoantibodies against IL-17A/F, IL-22 and type I interferons (IFN-α/ω) and impair Th17 antifungal immunity and tumor surveillance. This evidence concerns the gene AIRE and neoplasm.